Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Liabilities (2017 - 2025)

Autolus Therapeutics' Total Liabilities history spans 9 years, with the latest figure at $410.9 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 15.63% year-over-year to $410.9 million; the TTM value through Dec 2025 reached $410.9 million, up 15.63%, while the annual FY2025 figure was $410.9 million, 15.63% up from the prior year.
  • Total Liabilities reached $410.9 million in Q4 2025 per AUTL's latest filing, up from $396.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $410.9 million in Q4 2025 to a low of $92.2 million in Q4 2021.
  • Average Total Liabilities over 5 years is $258.3 million, with a median of $263.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: increased 9.54% in 2021, then surged 122.87% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $92.2 million in 2021, then surged by 107.72% to $191.6 million in 2022, then skyrocketed by 37.74% to $263.9 million in 2023, then soared by 34.67% to $355.4 million in 2024, then rose by 15.63% to $410.9 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Total Liabilities are $410.9 million (Q4 2025), $396.5 million (Q3 2025), and $374.5 million (Q2 2025).